14.06.2005 – 18:13

Intercell AG

euro adhoc: Intercell AG
other
$ 6.6 million R&D grant from US NIH for Intercell to develop biodefense vaccines

Disclosure announcement transmitted by euro adhoc.
  The issuer is responsible for the content of this announcement.

14.06.2005

Vienna - June 14, 2005 - Intercell AG announced today the receipt of
an R&D grant from the National Institute of Health (NIH) of the
United States amounting to $ 6.6m. The grant supports the
incorporation of Intercell’s proprietary adjuvant program (IC31TM)
into the development of biodefense vaccines. In the event of a
bioterror attack effective single dose vaccines with reduced antigen
doses and safe immune protection are required for mass immunization.

The major goal of the NIH-funded project is the incorporation of
Intercell’s novel "Immunizer" IC31TM adjuvant into vaccine
applications to mediate the induction of intensified and specific
immune responses. The three year R&D program will include a
proof-of-concept study combining IC31TM with Intercell’s existing
prophylactic Japanese Encephalitis Virus (JEV) vaccine to create
biodenfense related applications.

Intercell’s proprietary IC31TM comprises a peptide and an
oligonucleotide for stimulating both potent B-cell and T-cell immune
responses.

"This is the largest NIH R&D grant ever awarded to an Austrian
biotechnology company. It shows that our adjuvant program and one of
our most advanced vaccine products have been recognized for their
strong potential to protect people in hazardous situations that go
beyond standard prophylactic applications", states Gerd Zettlmeissl,
Intercell’s COO.

About Intercell AG
Intercell AG is a fast growing biotechnology company focusing on the
design and development of novel vaccines for prevention and treatment
of diseases with substantial unaddressed medical need. The Company’s
unique position is based on proprietary technology platforms and its
in-house GMP manufacturing facilities. Intercell’s technology has
been endorsed by collaborative agreements with a number of global
pharmaceutical companies, including Sanofi Aventis, and Merck&Co.,
Inc. The superior adjuvant profile of IC31TM has led to promising
product alliances with the Statens Serum Institut in Denmark for the
development of a novel TB vaccine and with Scigen Ltd in Australia in
the field of Hepatitis B. The Company has a broad development
pipeline. The lead product - a prophylactic vaccine against Japanese
Encephalitis (JEV) is about to enter Phase III clinical trials. JEV
is a flavivirus that is the leading cause of encephalitis worldwide
resulting in 50,000 cases and 15,000 deaths annually and has been
classified as a Pathogen for Biodefense. The second lead product -  a
vaccine against Hepatitis C - is currently undergoing Phase II
clinical trials.  Five additional follow up product candidates
focusing infectious diseases in the pre-clinical phase fill the
pipeline. Intercell is listed on the Vienna stock exchange under the
symbol "ICLL".

For more information please visit: www.intercell.com

This communication expressly or implicitly contains certain
forward-looking statements concerning Intercell AG and its business.
Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Intercell AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Intercell AG is providing this communication as of this date and does
not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained herein is not for publication or
distribution in the United States of America. This press release is
not an offer of securities for sale in the United States. Securities
may not be offered or sold in the United States absent registration
or an exemption from registration under the U.S. Securities Act of
1933, as amended. Any public offering of securities to be made in the
United States will be made by means of a prospectus that may be
obtained from Intercell AG and that will contain detailed information
about the company and management, as well as financial statements.

end of announcement                    euro adhoc 14.06.2005 17:34:00 

Further inquiry note:

Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN:
Index:
Börsen: Wiener Börse AG / official market